NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.

I. CALL TO ORDER

12:00 PM
A. Roll Call & Introductions
B. Approval of Agenda
C. Conflict of Interest Update (see posted slides)
D. Conflict of Interest Declaration
E. Approval of Minutes
F. Legislative and Department Update

R. Citron (OSU)
R. Citron (OSU)
A. Alpaugh (DOJ)
R. Citron (OSU)
R. Citron (OSU)
T. Douglass (OHA)

1:00 PM
II. CONSENT AGENDA TOPICS

J. Slater (Chair)

A. P&T Annual Report
B. Orphan Drug Policy Updates
1. Crysvita® (burosumab-twza)
2. Brineura® (cerliponase alfa)
3. Reblozyl® (luspatercept)
4. Public Comment

R. Citron (OSU)

III. PREFERRED DRUG LIST NEW BUSINESS

1:05 PM
A. Parkinson’s Disease Class Update with New Drug Evaluation
1. Class Update/Prior Authorization Criteria
3. Public Comment
4. Discussion of Clinical Recommendations to OHA

A. Gibler (OSU)

1:25 PM
B. Cystic Fibrosis Class Update with New Drug Evaluation
1. Class Update/Prior Authorization Criteria
2. Trikafta™ (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) New Drug Evaluation
3. Public Comment
4. Discussion of Clinical Recommendations to OHA

M. Herink (OSU)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 1:45 PM| C. **Oral Diuretics Class Update** | 1. Class Update  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA | S. Fletcher (OSU)  |
| 2:00 PM| D. **Gamifant™ (emapalumab-lzsg) New Drug Evaluation** | 1. New Drug Evaluation/Prior Authorization Criteria  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA | D. Engen (OSU)  |
| 2:15 PM| E. **Laxatives for Chronic Constipation Class Update** | 1. Class Update/Prior Authorization Criteria  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA | D. Moretz (OSU)  |
| 2:35 PM| BREAK                            |                                                                         |                    |
| 2:45 PM| IV. **DUR NEW BUSINESS**         |                                                                         |                    |
| 2:45 PM| A. **Hepatitis C, Direct-Acting Antivirals Policy Evaluation** | 1. Literature Scan/Prior Authorization Criteria  
2. Policy Evaluation  
3. Public Comment  
4. Discussion of Clinical Recommendations to OHA | M. Herink (OSU)  
A. McKenzie (OSU)  |
| 3:15 PM| B. **Dose Consolidation Policy Proposal** | 1. Policy Proposal  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA | S. Fletcher (OSU)  |
2. Drug Use Evaluation  
3. Public Comment  
4. Discussion of Clinical Recommendations to OHA | D. Nagarkatti-Gude &  
N. Kashey (MHCAG)  
S. Servid (OSU)  |
| 3:45 PM| D. **Fluoroquinolones Drug Use Evaluation** | 1. Drug Use Evaluation  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA | K. Sentena (OSU)  |
| 4:00 PM| V. **DUR OLD BUSINESS**          |                                                                         |                    |
| 4:00 PM| A. **Antidepressants Safety Edit Update** | 1. MHCAG Meeting Minutes  
2. Spravato™ ( esketamine) Safety Edit  
3. Zulresso™ ( brexanolone) Safety Edit  
4. Public Comment  
5. Discussion of Clinical Recommendations to OHA | S. Servid (OSU)  |
VI. EXECUTIVE SESSION

VII. RECONVENE for PUBLIC RECOMMENDATIONS

VIII. ADJOURN

IX. OHA RULES ADVISORY COMMITTEE

1. Public Comment